| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $83M | ||
| $63M |
Buys | $53,036,612 | 36 | 100 |
Sells | $0 | 0 | 0 |
| AKKARAJU SRINIVAS | director | 15 | $20.55M | 0 | $0 | $20.55M |
| Foresite Capital Management VI LLC | 10 percent owner | 7 | $10.83M | 0 | $0 | $10.83M |
| Foresite Labs, LLC | 10 percent owner | 7 | $10.83M | 0 | $0 | $10.83M |
| Tananbaum James B. | 7 | $10.83M | 0 | $0 | $10.83M |
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
Over the last 12 months, insiders at Alumis Inc. Common Stock have bought $53.04M and sold $0 worth of Alumis Inc. Common Stock stock.
On average, over the past 5 years, insiders at Alumis Inc. Common Stock have bought $26.63M and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: AKKARAJU SRINIVAS (director) — $20.55M. Foresite Capital Management VI LLC (10 percent owner) — $10.83M. Foresite Labs, LLC (10 percent owner) — $10.83M.
The last purchase of 588,235 shares for transaction amount of $10M was made by AKKARAJU SRINIVAS (director) on 2026‑01‑09.
| 2026-01-09 | AKKARAJU SRINIVAS | director | 588,235 0.4897% | $17.00 | $10M | +32.92% | ||
| 2026-01-08 | Tananbaum James B. | 411,764 0.3688% | $17.00 | $7M | +42.24% | |||
| 2026-01-08 | Foresite Labs, LLC | 10 percent owner | 411,764 0.3688% | $17.00 | $7M | +42.24% | ||
| 2026-01-08 | Foresite Capital Management VI LLC | 10 percent owner | 411,764 0.3688% | $17.00 | $7M | +42.24% | ||
| 2025-12-05 | AKKARAJU SRINIVAS | director | 186,377 0.0992% | $9.84 | $1.83M | +121.36% | ||
| 2025-12-04 | AKKARAJU SRINIVAS | director | 66,027 0.0292% | $8.18 | $540,101 | +195.42% | ||
| 2025-12-03 | AKKARAJU SRINIVAS | director | 100,000 0.0419% | $7.75 | $775,000 | +212.69% | ||
| 2025-12-02 | AKKARAJU SRINIVAS | director | 96,000 0.0392% | $7.55 | $724,800 | +230.77% | ||
| 2025-12-01 | AKKARAJU SRINIVAS | director | 86,350 0.0348% | $7.46 | $644,171 | +232.86% | ||
| 2025-11-28 | AKKARAJU SRINIVAS | director | 38,702 0.016% | $7.64 | $295,683 | +218.38% | ||
| 2025-11-26 | AKKARAJU SRINIVAS | director | 48,537 0.0201% | $7.64 | $370,823 | +219.11% | ||
| 2025-11-21 | Tananbaum James B. | 72,212 0.0288% | $7.38 | $532,925 | +231.10% | |||
| 2025-11-21 | Foresite Labs, LLC | 10 percent owner | 72,212 0.0288% | $7.38 | $532,925 | +231.10% | ||
| 2025-11-21 | Foresite Capital Management VI LLC | 10 percent owner | 72,212 0.0288% | $7.38 | $532,925 | +231.10% | ||
| 2025-11-20 | AKKARAJU SRINIVAS | director | 125,743 0.049% | $7.20 | $905,350 | +247.04% | ||
| 2025-11-19 | Tananbaum James B. | 190,500 0.0676% | $6.56 | $1.25M | +263.17% | |||
| 2025-11-19 | Foresite Labs, LLC | 10 percent owner | 190,500 0.0676% | $6.56 | $1.25M | +263.17% | ||
| 2025-11-19 | Foresite Capital Management VI LLC | 10 percent owner | 190,500 0.0676% | $6.56 | $1.25M | +263.17% | ||
| 2025-11-19 | AKKARAJU SRINIVAS | director | 137,772 0.0489% | $6.56 | $903,784 | +263.17% | ||
| 2025-11-18 | Tananbaum James B. | 117,374 0.0393% | $6.19 | $726,545 | +271.22% |
| Tananbaum James B. | 5702536 4.631% | $142.51M | 7 | 0 | ||
| Foresite Capital Management VI LLC | 10 percent owner | 5702536 4.631% | $142.51M | 7 | 0 | |
| Foresite Labs, LLC | 10 percent owner | 5702536 4.631% | $142.51M | 7 | 0 | |
| AKKARAJU SRINIVAS | director | 1853488 1.5052% | $46.32M | 15 | 0 | |
| Babler Martin | President, CEO and Chairman | 106454 0.0864% | $2.66M | 1 | 0 | |
| Colowick Alan | director | 18404 0.0149% | $459,915.96 | 2 | 0 | <0.0001% |
$11,588,217 | 69 | 42.07% | $3.23B | |
$11,583,737 | 45 | 49.75% | $3.76B | |
$104,428,685 | 44 | 22.55% | $3.48B | |
$148,770,544 | 34 | 80.63% | $3.02B | |
$1,275,975,557 | 32 | 19.44% | $3.78B | |
$62,927,079 | 29 | 14.02% | $2.73B | |
$137,061,250 | 16 | 23.01% | $3.04B | |
$112,580,865 | 16 | 0.64% | $3.69B | |
$18,336,420 | 12 | 24.03% | $3.09B | |
$1,248,715 | 10 | 5.66% | $2.69B | |
$45,445,266 | 9 | -24.96% | $2.98B | |
$32,575,266 | 8 | 37.03% | $2.86B | |
$91,589,325 | 7 | -6.97% | $3.37B | |
$666,380 | 5 | -16.60% | $2.68B | |
$3,200,000 | 5 | -11.36% | $3B | |
$24,000,085 | 4 | 33.26% | $2.74B | |
$142,493,653 | 3 | 4.30% | $3.33B | |
$9,900,000 | 1 | -7.19% | $3.26B | |
Alumis Inc. Common Stock (ALMS) | $17,235 | 1 | -51.12% | $3.08B |
| Increased Positions | 78 | +56.12% | 15M | +19.34% |
| Decreased Positions | 58 | -41.73% | 13M | -16.16% |
| New Positions | 30 | New | 10M | New |
| Sold Out Positions | 26 | Sold Out | 8M | Sold Out |
| Total Postitions | 159 | +14.39% | 80M | +3.18% |